New citrate solution aims to make kidney dialysis safer for Bleeding-Risk patients
NCT ID NCT05399537
First seen Jun 24, 2026 · Last updated Jul 28, 2026 · Updated 5 times
Summary
This phase 3 trial is testing Prismocitrate 18, a special fluid used during continuous kidney dialysis to prevent blood clots in the dialysis machine. The study will enroll 40 adults with acute kidney injury who need dialysis and cannot use standard blood thinners. Researchers will monitor for dangerous calcium imbalances and citrate buildup over up to 10 days of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Prismocitrate 18 (a citrate-based solution used to prevent blood clotting during kidney dialysis)
- What this could lead to
- If successful, this could confirm a safer way to prevent blood clots during continuous kidney dialysis, reducing bleeding risks for patients who cannot use standard blood thinners.
- What could go wrong
- This is a small, early-phase safety study with only 40 participants, so results may not apply to all patients. There are known risks of calcium imbalances (too low or too high) and citrate buildup, which could cause serious symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY (AKI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bon Secours Mercy Health-Springfield Regional Medical Center
ACTIVE_NOT_RECRUITINGSpringfield, Ohio, 45504, United States
-
Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
-
Gamma Medical Research, Inc / McAllen Medical Center
ACTIVE_NOT_RECRUITINGMcAllen, Texas, 78503, United States
-
Geisinger Medical Center
WITHDRAWNDanville, Pennsylvania, 17822, United States
-
Lt. Col. Luke Weathers, Jr. VA Medical Center
RECRUITINGMemphis, Tennessee, 38104, United States
-
Medical University of South Carolina (MUSC)
RECRUITINGCharleston, South Carolina, 29425, United States
-
Methodist Dallas Medical Center
NOT_YET_RECRUITINGDallas, Texas, 75203, United States
Contact Email: •••••@•••••
-
Penn State Hershey Medical Center
WITHDRAWNHershey, Pennsylvania, 17033, United States
-
University of Alabama at Birmingham/UAB
RECRUITINGBirmingham, Alabama, 35294-0007, United States
-
University of California Los Angeles
WITHDRAWNLos Angeles, California, 90095, United States
-
University of Miami
NOT_YET_RECRUITINGMiami, Florida, 33136, United States
-
University of Michigan
NOT_YET_RECRUITINGAnn Arbor, Michigan, 48109, United States
-
University of Southern California (USC) / Keck Hospital
RECRUITINGLos Angeles, California, 90033, United States
-
VA Pittsburgh Healthcare System
ACTIVE_NOT_RECRUITINGPittsburgh, Pennsylvania, 15240, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a discharge template and chat messages improve kidney injury recovery?
- Blood pressure swings during surgery linked to kidney damage risk
- Can extra protein save muscle in dialysis patients?
- New blood thinner may improve dialysis outcomes in sepsis patients
- New dialysis protocol could reduce electrolyte imbalances in ICU kidney patients
- Massive trial aims to settle debate: which common surgery drug saves kidneys?